Marc Davis, the editor of popular resource site www.CannabisCapitalist.ca, interviewed Emerald Health Therapeutics Inc (CVE:EMH)’s CEO and President, Mr. Bin Huang, PhD, MBA. During this interview, Huang reported that her firm is a leader in the race to advance pharmaceutical-grade medical formulas from the cannabis crop to address sleep disorders and chronic pain. To this end, the firm has a robust science-driven focus.
Emerald Health is on-track to market slow-release, standardized-dose medicinal marijuana capsules for the growing nutraceutical market in this year. When asked about what competitive edge does company has over rival licensed manufacturers that are trying to advance nutraceutical and medicinal formulas from cannabis, Huang said that they are a science-driven firm and they possess a strong background in scientific research and product development in the biopharmaceutical market.
For example, their head of Research & Development segment is Frey Garabagi, who is an expert in cannabis research & development, and cultivation. He is extremely passionate about cannabis and boasts a PhD degree from the University of Guelph which comes in the list of the best universities for plant biology.
Emerald Health CEO said that Garabagi is extremely accomplished and has patents on manufacturing biopharmaceutical products from crops. For instance, he has patents for utilizing crop to develop antibodies to fight breast cancer. Garabagi’s great depth of knowledge and extensive experience in biopharmaceuticals, molecular genetics and plant biology are rare and extremely valuable to company.
Between board members and management, they are able to depend on a great team that’s constituted of medical doctors, pharmacist and plant scientists. The team has an in depth experience in the biopharmaceutical industry, particularly with advancing innovative medicines.
Emerald Health even benefit from a thorough understanding of the regulatory environment in the U.S. and Canada, and globally, for drug development, as well as the advancement of nutraceuticals.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: